Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease  by Mao, Qinwen et al.
Intracellular tra⁄cking of CLN3, the protein underlying the childhood
neurodegenerative disease, Batten disease
Qinwen Maoa, Haibin Xiaa, Beverly L. Davidsona;b;c;
aDepartment of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242, USA
bDepartment of Neurology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
cDepartment of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, IA 52242, USA
Received 26 August 2003; revised 28 October 2003; accepted 29 October 2003
First published online 12 November 2003
Edited by Felix Wieland
Abstract Juvenile neuronal ceroid lipofuscinoses (Batten dis-
ease) is a progressive neurodegenerative disorder resulting from
mutations in the CLN3 gene, which encodes a hydrophobic 438
amino acid protein of unknown function. Prior studies have
shown that CLN3 is expressed in multiple tissues, with highest
levels in brain and testis. Experiments using cells overexpressing
CLN3 indicate that CLN3 is a lysosomal resident protein. How-
ever, studies to date have not addressed tra⁄cking of endoge-
nous CLN3. As such, the purpose of the present study was two-
fold. First, to develop a culture model to allow evaluation of
native CLN3 transport. Second, to utilize available epitope-spe-
ci¢c antibodies to determine if CLN3 reaches the plasma mem-
brane en route to the lysosome. Our data using a NCCIT (em-
bryonic testicular carcinoma) cell model coupled with surface
biotinylation and antibody trapping demonstrated that at least
a proportion of CLN3 tra⁄cks to the lysosome via the cell
membrane. Moreover, inhibition of the W3A subunit of the
AP-3 adapter protein complex increased levels of CLN3 at
the cell surface.
2 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The neuronal ceroid lipofuscinoses (NCLs) are inherited
neurodegenerative disorders characterized by the accumula-
tion of auto£uorescent lipopigments in many cell types and
notably neurons [1]. In the past, the NCLs were classi¢ed
exclusively on the basis of the age of onset and clinical patho-
logical features, for example the electron microscopy pro¢le of
the storage deposits in biopsy tissue. More recently, the iden-
ti¢cation of genes causative of these disorders has assisted
with appropriate diagnoses [2^5].
Batten disease, the juvenile onset form of NCL (ceroid lipo-
fuscinosis type III), is the most common of this class of ly-
sosomal storage diseases. Clinical onset typically initiates with
visual failure at approximately 4^6 years followed by seizures
and progressive mental decline. Magnetic resonance imaging
studies show progressive cerebral atrophy, and patients gen-
erally succumb by the second or third decade of life [6].
The Batten disease gene (CLN3) contains 15 exons and
encodes a 1689 bp product [2]. Biochemical studies to assess
the topology revealed an extremely hydrophobic 438 amino
acid protein having ¢ve transmembrane-spanning domains [7].
The CLN3 transcript has no notable homology with other
proteins [2] and is conserved amongst Saccharomyces cerevi-
siae, Caenorhabditis elegans, Drosophila, mouse and dog, and
other species.
Recent work on transfected or viral vector-infected cells
showed that CLN3 is a resident lysosomal enzyme, co-local-
izing with lysosomal markers LAMP-1, LIMP II and cathep-
sin D in non-neuronal cells [8^10] and synaptophysin in neu-
ronal cell lines [10]. Most patients with CLN3 de¢ciency
harbor a 1.02 kb deletion on both alleles [2], with overex-
pressed mutant protein retained in the endoplasmic reticulum
(ER) [9]. Interestingly, lesions representative of the most com-
mon point mutations did not grossly impair lysosomal target-
ing using yeast as a model system [10]. Although well-estab-
lished that the loss of functional CLN3 leads to a lysosomal
storage disease characterized by the accumulation of auto-
£uorescent inclusions containing in part adenosine triphos-
phate (ATP) synthase subunit c [11], the mechanisms under-
lying neuronal degeneration as a consequence of the de¢ciency
remain equivocal.
Following their transit through the Golgi complex, newly
synthesized lysosomal membrane proteins reach late endo-
somes and/or lysosomes through direct transport from the
trans-Golgi network via clathrin-coated vesicles, or indirect
transport via the secretory pathway to the plasma membrane
and endocytosis [12^16]. The cytoplasmic domains of trans-
membrane proteins contain tyrosine- and dileucine-based sort-
ing motifs that allow adaptor protein complex (AP) binding,
and appropriate segregation [17^19]. Both motifs are present
in the carboxy-terminus of CLN3. In mammalian cells, AP-1
and AP-3 can mediate vesicle membrane protein (e.g. LAMP-
1 and LIMP II) transport to endosomal and subsequently
lysosomal compartments [1,12,16,20]. Additionally, lysosomal
membrane proteins (e.g. LAMP-1) may tra⁄c to late endo-
somes and lysosomes via AP-2-dependent endocytosis after
¢rst being transported to the plasma membrane [21].
The development of hypotheses regarding how mutations in
CLN3 lead to disease would be aided substantially by under-
standing how native CLN3 reaches the lysosome. Initial stud-
ies on CLN3 tra⁄cking have utilized overexpression systems
because CLN3 is undetectable using available antibodies in
most cell types. Here, we capitalized on earlier work by Ler-
ner and colleagues demonstrating that CLN3 expression is
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highest in brain and testis [2] and found relatively robust
levels of CLN3 protein in NCCIT cells, an embryonic testic-
ular carcinoma cell line, relative to other cell lines tested. Our
data reveal that CLN3 reaches the lysosome via the plasma
membrane, and that plasma membrane localization can be
enhanced by inhibition of AP-3.
2. Materials and methods
2.1. Materials
Only analytical grade reagents were used. Retinoic acid (RA) was
purchased from Sigma (St. Louis, MO, USA). 30% (w/v) acrylamide,
1% (w/v) bisacrylamide solution was supplied from Bio-Rad Labora-
tories (Hercules, CA, USA). [32P]deoxycytidine triphosphate (dCTP)
(3000 Ci/mmol) was acquired from Amersham Pharmacia Biotech
(Piscataway, NJ, USA).
2.2. Cell culture
NCCIT (American Type Tissue Culture collection, Rockville, MD,
USA) cells were grown in RPMI 1640 medium supplemented with
10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and
100 units/ml streptomycin. RA (1035 M) was added to the medium to
induce di¡erentiation [22].
2.3. Antibodies and absorption tests
Dr. M. Bennett (Southwestern Medical Center, University of
Texas, Dallas, TX, USA) kindly provided the antibodies Q438 and
Q516. The rabbit polyclonal antibodies Q516 and Q438 were gener-
ated against synthetic peptides of human CLN3 protein sequence
corresponding to amino acids 2^18 (GGCAGSRRRFSDSEGEE;
CLN3.1) and 251^265 (QPLIRTEAPESKPGS; CLN3.3), respec-
tively.
Q438 and Q516 speci¢cities were con¢rmed by absorption of sera
with peptide-conjugated Sepharose beads. Peptides, 5 mg/ml, were
brought up in 50 Wl phosphate-bu¡ered saline (PBS). 5 Wl of normal
horse serum (NHS)-activated Sepharose 4 fast £ow (Pharmacia Bio-
tech, Uppsala, Sweden) were washed with 50 Wl ice-cold 1 mM HCl
and diluted in 100 Wl PBS. The washed beads and the peptide solution
were mixed and allowed to bind for 4 h at room temperature while
rotating end over end. Non-reacted groups were subsequently blocked
by incubation in 1 ml 0.05 M Tris bu¡er pH 7.4 overnight. Beads
were washed in 0.05 M Tris bu¡er pH 8 and 0.2 M acetate bu¡er pH
4, 150 Wl each, for a total of six repetitions.
2.4. Immunohistochemistry
For ABC immunostaining, NCCIT cells were ¢xed with 2% para-
formaldehyde in 0.1 M PBS pH 7.4 for 15 min at 4‡C, and rinsed
three times with ice-cold 0.01 M PBS pH 7.4. Cells were then incu-
bated with antibodies diluted with PBS containing 3% bovine serum
albumin (BSA) and 0.3% Triton X-100 overnight at 4‡C. The anti-
body dilutions are as follows: Q438, 1:1000; Q516, 1:500; monoclo-
nal antibody to human LAMP-1 (H4A3, from University of Iowa
Tissue Culture Hybridoma Facility), 1:4; polyclonal antibody from
rabbit to human mannose-6-phosphate receptor (M6PR) (kindly pro-
vided by Peter Lobel, Rutgers, NJ, USA), 1:1000. After rinsing three
times with PBS, cells were incubated in 1:200 biotinylated goat anti-
rabbit IgG (Vector Laboratories, Inc., Burlingame, CA, USA) fol-
lowed by incubation with ABC complex (Vector Laboratories, Inc.,
Burlingame, CA, USA). The complex was then reacted with diamino-
benzidine (DAB) and H2O2 (Sigma-Aldrich, St. Louis, MO, USA) in
the presence of nickel sulfate to give a dark blue precipitate according
to the kit manual. Sections were then mounted with GelMount me-
dium (Biomeda Corp, Foster City, CA, USA) and analyzed using a
Leica DM RBE. Images were acquired with a SPOT RT camera and
associated software (Diagnostic Instruments, Sterling Heights, MI,
USA).
For immuno£uorescence assay and confocal microscopy, NCCIT
cells were ¢xed and incubated with Q438 and H4A3 as above. The
secondary antibodies lissamine^rhodamine-conjugated goat anti-
mouse and £uorescein-conjugated goat anti-rabbit (Jackson Immuno-
research Laboratories, West Grove, PA, USA) were used at 1:200 in
diluent. Confocal microscopy was performed using a 40U objective
on a Zeiss LSM 510, with images captured using associated software.
2.5. Northern blots
Total RNA from NCCIT cells was prepared by using Trizol0 re-
agent (Gibco-BRL, Grand Island, NY, USA). A 534 bp probe speci¢c
for the 495^1029 region of human CLN3 was cloned into pMCG-16
by polymerase chain reaction (PCR) using a primer pair, 5P-AAA-
GAATTCATGGGGGAGTCACCTTCCTC-3P and 5P-AAAGAAT-
TCTCAACGGATGCGACAGCAGCG-3P. The probe was generated
using a random primed DNA labeling kit (Boehringer Mannheim,
Indianapolis, IN, USA) according to the kit manual. Hybridizations
were performed in Northern Max-Plus following the manufacturer’s
instructions (Ambion, Dallas, TX, USA).
2.6. Antibody uptake experiments
NCCIT cells were grown on plastic Petri dishes (60 mm) and
treated with RA for 48 h. Q438 (1:1000) and Q516 (1:500) were
then added to the culture medium. The cells were incubated at 37‡C
for 1, 2, or 6 h, then washed and processed for immunostaining, im-
munoprecipitation, or biotinylation. For immunostaining, the cells
were ¢xed with 2% paraformaldehyde in 0.1 M PBS, pH 7.4 for 15
min at 4‡C. Biotinylated goat anti-rabbit IgG diluted in PBS, 0.3%
Triton X-100, was added for 1 h at 4‡C, followed by incubation with
ABC complex and reaction with DAB in the presence of nickel sul-
fate.
For immunoprecipitation, cells were washed and proteins extracted
without phase separation. Brie£y, extracts were prepared by incubat-
ing cells in ice-cold Tris-bu¡ered saline (TBS) (10 mM Tris, pH. 7.4,
0.15 M NaCl) containing 1 mM ethylenediamine tetraacetic acid
(EDTA,) 1% (vol/vol) Triton X-114, and protease inhibitors (see be-
low) for 45 min on ice. Extracts were transferred to Eppendorf tubes
and clari¢ed by centrifugation at 14 000Ug for 10 min at 4‡C. Protein
A-Sepharose was then added to the cell lysates for 2 h at 4‡C. The
immune complexes were pelleted, washed, eluted with lithium dodecyl
sulfate (LDS) sample bu¡er, and subjected to LDS^polyacrylamide
gel electrophoresis followed by Western blotting (see below).
2.7. Western blot
For Western analysis, all samples were diluted to 1 mg/ml protein in
1% LDS (Sigma-Aldrich, St Louis, MO, USA), 5% L-mercaptoetha-
nol, 5% glycerol, 0.025% bromophenol blue, and 0.035 M Tris^HCl
(pH 6.8) and incubated for 30 min at room temperature. Samples
were subjected to LDS^PAGE on 12% gels and transferred to nitro-
cellulose. Nitrocellulose sheets were blocked with 5% non-fat dry milk
for 1 h in PBS containing 0.1% (vol/vol) Tween 20. Primary anti-
bodies Q438 (1:2000) or Q516 (1:1000) were added and incubated
for 1 h at room temperature. Detection was enhanced by chemilumi-
nescence using horseradish peroxidase conjugated to anti-rabbit IgG
(Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA).
2.8. Biotinylation and streptavidin precipitations
NCCIT cells were washed four times with ice-cold PBS containing
0.1 mM CaCl2 and 1 mM MgCl2 (PBS-C/M). Sulfo-NHS-biotin
(Pierce, Rockford, IL, USA) 0.5 mg/ml in ice-cold PBS-C/M was
added to the dishes for 30 min at 4‡C. Cells were then washed once
with serum-free media and three times with PBS-C/M [23] and ex-
tracted with phase separation as described below. Approximately 50
Wl of immobilized streptavidin (6% cross-linked agarose, Pierce, Rock-
ford, IL, USA) was added to 1 ml of cell lysate and allowed to bind
overnight at 4‡C while rotating end over end. After binding, immo-
bilized streptavidin was recovered by centrifugation (14 000Ug for
30 s) and washed (¢ve times) with ice-cold TBS, pH 8.0, containing
1% (vol/vol) Triton X-100. The addition of 100 Wl Laemmli sample
bu¡er and three rounds of agitation and boiling (5 min each) eluted
bound proteins. Fresh 2-mercaptoethanol was added after each boil-
ing step to a ¢nal concentration of 5% (vol/vol) [23].
2.9. Phase separation
Washed NCCIT cells were extracted with ice-cold TBS (10 mM
Tris, pH 7.4, 0.15 M NaCl) containing 1 mM EDTA, 1% (vol/vol)
Triton X-114, protease inhibitors (20 Wg/ml leupeptin, 10 Wg/ml pep-
statin, 10 Wg/ml papain, 176 Wg/ml phenylmethylsulfonyl £uoride) at
2^5U107 cells/ml for 45 min on ice. Cell extracts were transferred to
Eppendorf tubes and clari¢ed by centrifugation (14 000Ug for 10 min)
at 4‡C. To separate phases, the lysate was warmed to 32‡C for 3 min
and centrifuged at 10 000Ug for 20 s at room temperature. The aque-
ous phase (upper) was removed and residual amphipathic proteins re-
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extracted by the addition of 100 Wl of 11% Triton X-114 followed by
an additional phase separation. The detergent phase was also re-ex-
tracted by the addition of a 10-fold volume of TBS with 1 mM
EDTA, protease inhibitors (see above) and 0.06% Triton X-114 [6,24].
2.10. Antisense experiments
Selective inhibition of the W3A subunit of AP-3 was used essentially
as described by Le Borgne et al. [12]. Brie£y, phosphorothioate-modi-
¢ed oligodeoxynucleotides were synthesized (IDT, Santa Clara, CA,
USA). The sequence sites selected were centered on the initiation
ATG (ATG antisense) and on a non-overlapping site located imme-
diately downstream (inner antisense), deduced from the human W3A.
A reversed ATG antisense was synthesized as the control oligonucleo-
tide (reversed antisense). Cells were incubated for 48 h with 5 WM
ATG antisense together with 5 WM inner antisense, 10 WM reversed
antisense only, or left untreated. Fresh oligonucleotides were added
every 24 h. Oligonucleotide sequences are as described in Le Borgne et
al. [12].
3. Results
3.1. Native CLN3 expression in NCCIT cells
The study of CLN3 tra⁄cking would be greatly aided by
the availability of cell lines expressing immunologically detect-
able levels of CLN3. We screened numerous cell lines and
found that the testicular cancer cell line, NCCIT, expressed
signi¢cant levels of human CLN3 (Fig. 1A, top left panel). As
was found previously with other integral lysosomal membrane
proteins [25], the induction of di¡erentiation by the addition
of RA substantially increased CLN3 immunoreactivity (Fig.
1A). The most notable rise in expression was at 1 day post
addition of RA with intense intracellular CLN3 immunoreac-
tivity (Fig. 1A, top right panel). At later time points (studies
to 14 days), CLN3 immunoreactivity was reduced and punc-
tate, re£ective of its known lysosomal localization in non-neu-
ronal cells (Fig. 1B). The increase in CLN3 expression could
be attributed in part to increased mRNA expression (Fig. 1C).
3.2. Antibody-induced capping of CLN3
The lumen of vesicular compartments along the biosyn-
thetic secretory and endocytic pathways is topologically equiv-
alent to the exterior of the cell. Recent experiments have
shown that CLN3 is a type IIIB transmembrane protein con-
taining ¢ve transmembrane domains [7]. As such, Q516, which
recognizes amino acids 2^18, is directed to an extracellular or
Fig. 1. CLN3 expression in RA-induced NCCIT cells. NCCIT cells were stained with anti-CLN3 antibody Q438 (A), 1, 2 and 3 days later fol-
lowing mock treatment (left panels) or induction with RA (right panels). Lower panels, anti-CLN3 antibody pre-absorbed to immunizing pep-
tides. B: CLN3 co-localizes with LAMP-1. NCCIT cells were di¡erentiated with RA for 3 days, and immuno£uorescence with LAMP-1 (red,
a) and Q438 (green, b) evaluated by confocal microscopy. c is the merged image. Bar, 25 Wm. C: Northern blot for CLN3-speci¢c or GAPDH-
speci¢c RNA in RA-induced NCCIT cells. RNA was prepared 1 or 3 days after RA treatment.
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intraluminal epitope. We took advantage of the Q516 epitope
speci¢city to test if CLN3 is transported to the cell surface.
RA-treated NCCIT cells were incubated with Q516 for 1, 2 or
6 h, after which the cells were ¢xed, permeabilized and stained
with biotinylated goat anti-rabbit IgG. Capping of the anti-
gen^antibody complex, as represented by the photomicro-
graphs in Fig. 2, was evident in approximately 1^5% of cells
at all time points (not shown and Fig. 2). Internalized anti-
body was also evident, although in a smaller percentage of the
cells. When RA-treated NCCIT cells were incubated with the
antibody Q438, which recognizes a cytoplasmic epitope, nei-
ther capping nor internalization was evident (data not shown).
Immunoprecipitation and surface biotinylation experiments
con¢rmed that CLN3 tra⁄cked to the cell surface after in-
duction of di¡erentiation with RA. RA-treated NCCIT cells
were incubated with Q516 or Q438 for 1, 2 (not shown) or 6 h
at 37‡C, harvested, and cell extracts (see Section 2) reacted
with protein G coupled to Sepharose beads. The immunocom-
plex was dissociated and electrophoresed through 12% LDS
gels, blotted onto nitrocellulose, and incubated with Q438 to
detect CLN3. Fig. 3A is representative of all time points, and
shows that CLN3 could be immunoprecipitated when NCCIT
cells were incubated with Q516 (lane 2) but not when incuba-
ted with bu¡er alone or Q438 (lanes 1 and 3, respectively).
When NCCIT cells were surface biotinylated after Q516 in-
cubation, the amount of streptavidin^biotin-linked CLN3 pre-
cipitate was greatly increased (Fig. 3B, compare lanes 1 and
2). Together, the data suggest that CLN3 is transported to the
cell surface in RA-induced NCCIT, and that incubation with
antibodies targeted to extracellular epitopes enhanced surface
expression further. Our results also con¢rm the topology of
CLN3 predicted from in vitro transcription/translation experi-
ments [7].
3.3. The role of AP-3 in CLN3 tra⁄cking
CLN3 is predominantly lysosomal in di¡erentiated NCCIT
cells, with very little surface staining evident (Fig. 1). To test if
CLN3 tra⁄cking to the lysosome occurs via an AP-3-depen-
dent mechanism, NCCIT cells were cultured in antisense oli-
gonucleotides targeted against the W3A subunit of AP-3 using
methods previously described by Le Borgne and colleagues
[12]. In Fig. 4, representative photomicrographs demonstrate
that incubation of NCCIT cells in AP-3 antisense oligonucleo-
tides caused increased surface expression of CLN3 and
LAMP-1 (b and e), but not the M6PR (h), a receptor known
to use AP-1-dependent pathways [13,14]. Western blotting
and immunostaining con¢rmed inhibition in W3A subunit ex-
pression (data not shown). Incubation of cells in control oli-
gonucleotides (reverse antisense) did not change the extent of
surface expression (Fig. 4c, f, and i). When cells treated with
AP-3 antisense oligonucleotides were subsequently incubated
with antibodies directed against extracellular epitopes, inter-
nalization of the antibody was evident when directed against
CLN3 (Fig. 5b) or LAMP-I (e). Incubation with control oli-
gonucleotides (Fig. 5c and f, for CLN3 and LAMP-1, respec-
tively) was indistinguishable from untreated cells (Fig. 5a and
d). As expected, the presence or absence of AP-3 antisense
oligonucleotides did not a¡ect M6PR immunoreactivity.
To con¢rm the increased surface expression of CLN3 in the
presence of antisense AP-3 oligonucleotides, surface biotinyl-
ation studies were done. NCCIT cells were cultured in either
AP-3 antisense or control oligonucleotides for 48 h followed
by biotinylation and extraction of the detergent soluble frac-
tion (see Section 2). Biotinylated proteins were immunopreci-
pitated with immobilized streptavidin followed by fractiona-
tion by LDS^PAGE gels and blotting to nitrocellulose. Blots
were probed with the anti-CLN3 antibody Q438. As shown in
Fig. 6, treatment of NCCIT cells with AP-3 antisense oligo-
nucleotides led to substantial increases in surface biotinylated
Fig. 2. Anti-CLN3 antibodies directed against an extracellular epitope of CLN3 induced capping on the surface of NCCIT cells. RA-induced
NCCIT cells were incubated in media with the anti-CLN3 antibody Q516. After 6 h, cells were ¢xed incubated with biotinylated goat anti-rab-
bit IgG and developed using DAB substrate. a^c are representative. Bar, 25 Wm. Similar results were seen in cells incubated with Q516 for 1 or
2 h (not shown).
Fig. 3. CLN3 tra⁄cks to the cell surface. A: Immunoprecipitation
of internalized antibody. RA-induced NCCIT cells were left in me-
dia alone (lane 1) or incubated in Q516 (lane 2) or Q438 (lane 3).
Cell extracts were prepared as described in Section 2, and CLN3
immunoprecipitated with protein A. The immune complexes were
resolved by LDS^PAGE, blotted onto membranes, and CLN3 visu-
alized by immunoblotting (arrow). B: Surface biotinylation reagents
have access to CLN3 in NCCIT cells incubated with Q516, but not
Q438. RA-induced NCCIT cells were incubated in Q516 (lane 1) or
Q438 (lane 2), after which cell surface proteins were biotinylated
(lanes 1 and 2) or left untreated (lane 3). Biotinylated proteins were
isolated by incubation with streptavidin^agarose. The complex was
disrupted and fractionated by LDS^PAGE, and immunoblotted
with Q438.
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CLN3 (lane 2) while untreated (lane 1) or control oligonucleo-
tide-treated cells (lane 3) did not. Together, the data support a
role for AP-3 in tra⁄cking of endogenous CLN3 in di¡er-
entiated NCCIT cells.
4. Discussion
Three central ¢ndings emerged from these studies. First,
NCCIT cells provide a valuable tool for evaluating endoge-
Fig. 4. Distribution of CLN3, LAMP-1 and MPR in W3A antisense oligonucleotide-treated NCCIT cells. NCCIT cells were grown in media
alone (a, d, and g), or in the presence of antisense (b, e, and h) or control (c, f, and i) oligonucleotides as previously described by Le Borgne
and colleagues [12]. Representative photomicrographs of cells ¢xed, permeabilized and stained for CLN3 (Q516 Ab; a^c), LAMP-1 (d^f) or
M6PR (g^i) are shown. Arrowheads depict apparent surface staining. Bar, 25 Wm.
Fig. 5. Uptake of exogenous antibodies by NCCIT cells. NCCIT cells were grown in media alone (a, d, and g), or in the presence of W3A anti-
sense (b, e, and h) or control (c, f, and i) oligonucleotides. Antibodies to CLN3 (Q516), LAMP-1, or the M6PR were added to the culture me-
dium 48 h later for an additional 6 h. The cells were washed, ¢xed and permeabilized, and the internalized antibodies subsequently detected
with biotinylated goat anti-rabbit IgG as described (Section 2). Bar, 25 Wm.
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nous CLN3 activity, expression, and tra⁄cking. When
NCCIT cells were induced to di¡erentiate, CLN3-speci¢c
mRNA increased, as did the level of immunoreactive protein.
Second, a proportion of CLN3 tra⁄cked to intracellular com-
partments via the plasma membrane. Third, data using anti-
sense oligonucleotides directed against the W3A subunit of
AP-3 indicate that tra⁄cking of CLN3 in NCCIT cells occurs
in part through AP-3-dependent mechanisms.
Studies using virally infected or transfected cells with CLN3
expression driven from strong viral promoters showed that
CLN3 is lysosomal in non-neuronal cell lines [8^10]. However,
no prior work has addressed how CLN3 is reaching the lyso-
some. NCCIT cells are developmentally pluripotent and can
di¡erentiate into derivatives of all three embryonic germ
layers (i.e. ectoderm, mesoderm, and endoderm), and RA in-
duction leads to vimentin-positive cells (5^20%), glial ¢brillary
acid protein (GFAP)-positive cells (10^30%) and neuro¢la-
ment-positive cells (5%) [22]. The increase in CLN3 immuno-
reactivity in only 5% of this pluripotent line after RA induc-
tion re£ects that CLN3 expression is higher in some
di¡erentiated cell types relative to others. Indeed Lerner and
colleagues showed that CLN3 mRNA levels are not uniform
amongst various tissues [2]. In studies in developing rodents,
CLN3 immunoreactivity is highest in developing peripheral
nervous system (PNS) and central nervous system (CNS)
(Q. Mao and B.L. Davidson, unpublished results). It will be
interesting to study further the phenotype of NCCIT cells
induced to express higher levels of CLN3.
NCCIT cells show properties similar to F-9 embryonic car-
cinoma cells [25] as regards to the e¡ects of RA on lysosomal
membrane protein levels. In both cell lines, RA induction
leads to increased expression of LAMP-1 and LAMP-2 [25]
in only a proportion of cells, and detectable levels of
LAMP-1 at the cell surface [25]. We also noted detectable
levels of CLN3 on the cell surface of a proportion of NCCIT
cells after RA induction by immunohistochemistry (Fig. 1),
while only punctate intracellular staining was evident in
non-induced cells.
The addition of antibody speci¢c for an extracellular epi-
tope of CLN3 induced very large aggregates of CLN3 at the
cell surface (capping). Capping was not noted upon addition
of antibody directed against residues 251^265. This result cor-
roborated other work in our laboratory that showed the 251^
256 region of CLN3 is cytoplasmic, making it inaccessible to
extracellularly applied antibodies speci¢c for this epitope [7].
Together with the surface biotinylation studies, these data
support the idea that CLN3 in RA-induced NCCIT cells is
transported to the cell surface.
An unusual consequence of de¢ciency of CLN3, a protein
present in many cell types within multiple organ systems, is
neurodegeneration characterized by loss of vision, epilepsy
and progressive dementia. This highly hydrophobic protein
is present in greatest amount in brain and testis [2]. In cell
lines CLN3 has been shown to co-localize with LIMP II and
cathepsin D in late endosomes/lysosomes at the electron mi-
croscopy level, and with LAMP-1 and LAMP-2 using confo-
cal microscopy [9,10]. How is CLN3 transported to these
compartments? Could it be dileucine, leucine/isoleucine pairs,
or tyrosine-based motifs? Tyrosine-based sequences generally
are YXXx (tyrosine, any amino acids, bulky hydrophobic
amino acids), and are important for interaction with the adap-
tor protein subunits W1, W2, and W3, of AP-1 through -3,
respectively, for appropriate intracellular tra⁄cking of vesicle
membrane proteins [2,13,26]. Evaluation of the carboxy-ter-
minus of CLN3 reveals dileucine and leucine/isoleucine pairs,
and three tyrosine-based motifs, namely IYLVF, AYVNT,
and LYEGL. The IYLVF motif in CLN3 lies in a highly
hydrophobic region and is likely embedded within the mem-
brane [7]. The remaining two motifs are in the predicted cy-
toplasmic COOH-terminus. The AYVNT motif may not be a
true tyrosine-based motif, since there is considerable prefer-
ence for highly hydrophobic amino acids such as phenylala-
nine, leucine, methionine, valine, or isoleucine at the Y+3
position; threonine is only weakly hydrophobic. Interestingly,
the LYEGL motif is 100% homologous to the internalization
motif in hIGAK [17]. Further studies to test the role of the
LYEGL motif in CLN3 tra⁄cking are warranted.
The LL or LI pairs in CLN3 are unlikely candidates for
interactions with adaptor complexes. LL or LI pairs alone are
not su⁄cient for internalization [27]. Earlier work by Ho«ning
showed that AP-3-dependent internalization by LL or LI was
dependent on a similar pair of acidic residues DE or EE in the
34 and 35 position [27]. In contrast, the amino acids in the
34 and 35 positions for the LL or LI motifs in CLN3 are
isoleucine, leucine, or serine.
Together, our data are consistent with AP-3’s role in re-
cruitment of lysosomal membrane proteins from endosomal
compartments [28]. CLN3’s localization on both late endo-
somes and lysosomes, coupled with the surface biotinylation
and antibody capping experiments, suggests that a proportion
of CLN3 tra⁄cks to the plasma membrane, and that some
AP-3-dependent sorting to the lysosome occurs. Moreover, we
showed that disruption of the ubiquitous W3A subunit of the
AP-3 complex using previously described antisense ap-
proaches [12] caused increased routing of CLN3 to the plasma
membrane. LAMP-1 was similarly misrouted while M6PR
was not. Prior work by Dell’Angelica et al. demonstrated
the requirement of the human L3A subunit of the AP-3 com-
plex in tra⁄cking of lysosomal membrane proteins, and
showed that mutations in human L3A cause Hermansky^
Pudlack syndrome [28].
Recent studies in yeast have shown that a deletion of btn1
(yeast homolog of CLN3) leads to increased expression of
btn2, a distant homolog of the cytoplasmic protein hook1
Fig. 6. Incubation in W3A antisense oligonucleotides increased the
accessibility of CLN3 to surface biotinylation. NCCIT cells were in-
cubated in media alone (lane 1), W3A antisense (lane 2) or control
(lane 3) oligonucleotides for 48 h, after which cells were subjected
to surface biotinylation. Biotinylated proteins were isolated from ex-
tracts (detergent soluble) by incubation with immobilized strepta-
vidin, after which complexes were disassociated, fractionated by
LDS^PAGE and immunoblotted. CLN3 was visualized by incuba-
tion of blots with Q438 antibodies.
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[29]. In Drosophila, hook1 is important in the internalization
of the transmembrane protein boss (bride of sevenless), a li-
gand for the receptor tyrosine kinase sevenless on adjacent
cells [30,31]. Although we may speculate that CLN3 expres-
sion on the plasma membrane may lead to its speci¢c inter-
action with adjacent cells, there is little evidence to support
this idea. A second possibility for the increased expression of
btn2 in btn1v yeast is that vesicular transport in general is
disrupted. Over time, impaired vesicular transport could lead
to alterations in transport proteins secondarily as well as ac-
cumulation of storage material. The phenotype of CLN3 de-
¢ciency in humans supports this hypothesis, as the onset of
disease is delayed until well after the PNS and CNS have
formed. Thus, how an absence of CLN3, in the case of the
1.02 kb deletion, or reduced function, in the case of other
identi¢ed point mutations [10] causes the recessive neurode-
generative disease with juvenile onset remains paradoxical.
Our results, along with other studies on CLN3 biology, may
help resolve this problem.
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